The Effect of Sitagliptin on the Regression of Carotid Intima-Media Thickening in Patients with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation
Table 4
Results of multivariate logistic regression models for the regression of IMT of ≥0.10 mm from baseline at the end of the study.
Factor
Mean IMT
Right max IMT
Left max IMT
Adjusted odds ratio (95% CI)
P value
Adjusted odds ratio (95% CI)
P value
Adjusted odds ratio (95% CI)
P value
Age (1 year)
1.01 (0.95–1.06)
0.83
0.98 (0.94–1.02)
0.37
1.01 (0.97–1.06)
0.61
Gender (male/female)
1.99 (0.83–4.79)
0.12
0.67 (0.33–1.35)
0.26
1.02 (0.49–2.14)
0.95
Body mass index (1 kg/m2)
1.07 (0.95–1.20)
0.26
1.03 (0.94–1.13)
0.56
1.00 (0.91–1.10)
0.98
Estimated duration of diabetes (1 year)
1.02 (0.97–1.07)
0.42
0.99 (0.95–1.03)
0.65
1.02 (0.98–1.07)
0.26
Smoking (yes/no)
1.93 (0.67–5.52)
0.22
0.72 (0.30–1.74)
0.47
1.83 (0.77–4.35)
0.17
HbA1c (1 mmol/l)
1.04 (0.69–1.56)
0.87
1.07 (0.76–1.51)
0.68
1.00 (0.70–1.44)
0.99
Systolic BP (1 mmHg)
0.99 (0.96–1.02)
0.40
1.03 (1.01–1.06)
0.012
0.97 (0.94–0.99)
0.02
Total cholesterol (1 mmol/l)
0.64 (0.35–1.18)
0.16
1.11 (0.69–1.79)
0.68
1.19 (0.72–1.95)
0.49
HDL cholesterol (1 mmol/l)
0.44 (0.11–1.78)
0.25
1.19 (0.38–3.75)
0.76
0.69 (0.22–2.15)
0.52
Triglyceride (1 mmol/l)
0.92 (0.58–1.44)
0.71
0.87 (0.59–1.29)
0.5
1.00 (0.72–1.38)
1.00
eGFR (1 ml/min/1.73 m2)
1.01 (0.99–1.03)
0.27
1.00 (0.98–1.01)
0.74
1.01 (0.99–1.03)
0.22
Baseline cIMT (0.01 mm)
1.05 (1.03–1.08)
<0.001
1.02 (1.01–1.03)
<0.001
1.02 (1.01–1.03)
<0.001
Treatment group (sitagliptin treatment/conventional treatment)
3.58 (1.60–7.99)
0.002
2.02 (1.07–3.84)
0.031
2.38 (1.23–4.58)
0.01
ACE/ARB (yes/no)
1.10 (0.50–2.45)
0.81
0.86 (0.45–1.68)
0.67
1.31 (0.66–2.63)
0.44
Statins (yes/no)
0.76 (0.33–1.74)
0.51
1.27 (0.64–2.49)
0.49
0.88 (0.44–1.76)
0.72
Antiplatelets (yes/no)
0.34 (0.12–0.96)
0.04
0.79 (0.35–1.79)
0.57
0.40 (0.17–0.97)
0.042
OHA (yes/no)
0.55 (0.26–1.18)
0.12
0.83 (0.43–1.58)
0.56
0.53 (0.27–1.04)
0.064
Changes in systolic BP at 104 weeks from baseline (1 mmHg)
1.00 (0.98–1.03)
0.94
1.02 (1.00–1.04)
0.079
0.99 (0.97–1.01)
0.45
Changes in HbA1c at 104 weeks from baseline (1 mmol/l)
1.25 (0.84–1.87)
0.27
1.13 (0.80–1.60)
0.49
0.91 (0.64–1.29)
0.59
Changes in total cholesterol at 104 weeks from baseline (1 mmol/l)
0.97 (0.94–1.00)
0.051
0.99 (0.97–1.02)
0.45
0.99 (0.96–1.01)
0.30
Changes in HDL cholesterol at 104 weeks from baseline (1 mmol/l)
1.00 (0.97–1.02)
0.76
1.01 (0.99–1.03)
0.33
1.01 (0.98–1.03)
0.59
Changes in triglyceride at 104 weeks from baseline (1 mmol/l)
1.00 (0.99–1.00)
0.39
1.00 (1.00–1.01)
0.22
1.00 (0.99–1.01)
0.85
Multivariate logistic regression models were used to identify the determination of the regression of IMT of ≥0.10 mm from baseline at the end of the study. ACE/ARB, angiotensin-converting enzyme/angiotensin II receptor blocker; BP, blood pressure; IMT, intima-media thickness; eGFR, glomerular filtration rate; OHA, oral hypoglycemic agents.
